Document is current
Any future updates will be listed below
-
Authors
McLaughlin, Pamela M. J.
Klar, Maximilian
Zwimpfer, Tibor A.
Dutilh, Gilles
Vetter, Marcus
Marth, Christian
du Bois, Andreas
Schade-Brittinger, Carmen
Reuss, Alexander
Bommer, Claudine
Kurzeder, Christian
Heinzelmann-Schwarz, Viola https://orcid.org/0000-0002-4056-3225
-
Funding
Funding for this research was provided by:
Krebsforschung Schweiz (KFS-4586-08-2018-R)
Helsana
Stiftung fürstlicher Kommerzienrat Guido Feger
Roche
Reliable Cancer Therapies
Novartis
- License Information
-
More Information
Article History
Received: 25 January 2022
Accepted: 17 April 2022
First Online: 6 May 2022
Declarations
:
: The ENGOT-ov54/Swiss-GO-2/MATAO trial has been ethically approved in Switzerland, by Swissethics, lead Ethics Committee Nordwest-Zentralschweiz (EKNZ), BASEC no: 2020–00148. In Austria as ENGOT-ov54/Swiss-GO-2/AGO 65/MATAO(LOGOS), lead Ethics Committee of the Medizinischen Universität Innsbruck, EK Ref Nr: 1496/2020, submitted by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Austria. Both Swissmedic as well as the Bundesamt für Sicherheit im Gesundheitswesen (BASG) have approved the conduct of the trial in these countries as well. Approval for the conduct of the study in Germany is currently under review of the lead ethical committee of the Albert-Ludwigs-Universität Freiburg and das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), submitted by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Deutschland as ENGOT-ov54/Swiss-GO-2/AGO-OVAR26/MATAO(LOGOS), Antrags-Nr: 22–1004-AMG-ff multi.All participants are required to provide written informed consent to the site investigator before registration.
: not applicable.
: The authors declare that they have no competing interests.
